Ambiguity in Commercially Sensitive Information Classification: The Need for Sector-Specific Gradation Criteria Under India’s Competition Rules
[By Abeer Sharma] The author is a student of Rajiv Gandhi National University of Law, Punjab. Introduction Recently, a penalty of Rs 40 Lakhs was imposed by the Competition Commission of India (CCI) on Goldman Sachs for the offence of Gun Jumping based on the acquisition of equity and information rights without informing the CCI. The offence of Gun Jumping is provided under Section 6(2A) of the Competition Act, 2002, which stipulates that no combination shall be given effect to until the expiry of 210 days from the date of notification to the CCI. Goldman Sachs, through its AIF scheme-1, acquired optionally convertible debentures (less than 10% equity) under Biocon Biologics, wherein it had access to the board and shareholder meeting minutes (information rights). Furthermore, under the ‘solely as an investment’ exemption in the Combination Regulations, 2011, acquisitions of less than 10% equity are exempt from notification to the CCI. However, CCI found these information rights not to be ‘ordinary’ for shareholders, and classified them as Commercially Sensitive Information (CSI). This interpretation amounted to a significant shift, wherein certain acquisition or merger involving the sharing of CSI, regardless of the percentage of equity shares acquired, was required to be reported to the CCI. However, sharing of CSI, as prohibited under the new Combination Regulation of 2024, is defined through the CCI’s updated FAQs on combinations, part N of which provides a list, including information relating to prices, profit margins, sales, and terms with customers. Although this information criteria are uniformly applicable to all entities as recognised in the Beer Cartel Case, CSI differs from entity to entity depending on the functions performed by it and the industry in which it is involved. The ignorance of this distinction by the Combination Regulations and the updated FAQs creates a grey area, wherein acquirers are faced with ambiguity concerning the classification of information as CSI or not, based on their specific industry. Furthermore, this uncertainty results in a lowering of investments, as evidenced by a study, finding that firms perceiving uncertainty in regulatory policies as a major obstacle exhibit an approximately 2.5 percentage point lower investment rate compared to those not viewing uncertainty as an impediment. Considering the same, this article, by briefly discussing the concept of CSI, provides a sector-specific solution through changes under the Competition Act, 2002 and the Competition (Combinations) Regulations, 2024, for rectifying the uniform information criteria based on international precedent of the United Kingdom (U.K.) and European Union (EU) and further examines its application under the Indian antitrust regime. The Concept of CSI and its Blanket Sectorial Application CSI, as defined under Part N of CCI updated FAQs on Combinations of 2025, relates to information that is important for an undertaking to protect, maintain, or improve its competitive position in the market. Further, Part N also discusses what is excluded from CSI, which includes information that is readily ascertainable through appropriate means or information available to an ordinary shareholder of a company that is not considered by the management for commercial decision-making. However, these criteria can be ascribed as subjective due to their enforcement variability across industries. In light of this, the section contrasts industries selected to represent different market structures, such as: (a) oligopolistic digital/ automative markets, (b) hyperlocal/price-sensitive retail, (c) large national FMCG firms, and (d) pharmaceuticals depicting pricing/regulatory sensitivity. The reason behind choosing these industries was not their superficial similarity, but to test the robustness of CSI across market concentration, public observability, and strategic value. Building on this sectoral comparison, information concerning quality, sales, and market shares functions as CSI as per the FAQ’s and may be applicable in the automobile industry, where a company may consider its quality ratings and sales data as highly sensitive. This is due to the oligopolistic nature of the market, wherein even minor changes in sales numbers or quality indices can be used to realign pricing and financing by competitors. The same was observed in General Motors’ OnStar Smart Driver case from 2025, wherein driving behaviour and quality-related data were held to be highly sensitive competitive information. In contrast, within the bakery industry, quality ratings and sales data are often publicly available due to the entity’s reputational dependence on them. Moreover, they do not provide competitors with a significant strategic advantage because of hyperlocal and price-sensitive demand. A similar precedent can be observed with the Sweets Treats Bakery case study in Chicago, which experienced a 20% increase in sales after implementing a bakery management software that provided detailed tracking of customer reviews, depicting product quality and sales data. Additionally, the subjectivity of excluded information from CSI can be illustrated through the Fast-Moving Consumer Goods (FMCG) sector. For instance, Hindustan Unilever Limited (HUL) files annual reports, investor presentations and financial disclosures with the Securities and Exchange Board of India (SEBI), revealing details such as plant location and generic production capacity. However, this disclosure adds little strategic advantage because competitors focus instead on stock-keeping unit (SKU), level consumer insights (e.g., which wheat or pack size sells more), functioning as a CSI, rather than on how much wheat production is undertaken by HUL, which merely showcases its generic production capacity. By contrast, in the pharmaceutical industry, where pricing is highly sensitive and private medications compete with generic medications, information revealing production capacity can indeed provide rivals with an edge. It can help predict a company’s future strategy of undercutting prices, enabling counteractions such as pre-emptive price slashing or blocking contracts with distributors. A similar situation arose with the U.S. Pharma Company- Mylan, which conspired with Pfizer and Teva by entering into patent litigation settlements to deliberately delay the market entry of competitors’ epinephrine autoinjectors, strategically postponing its generic production. Therefore, the foregoing sectoral contrasts demonstrate that CSI is not a fixed or universal category, but one that turns on market concentration, the observability of information, and its strategic value within a particular industry. Information that is treated as competitively critical in an oligopolistic market may function as a routine in a fragmented









